CureVac (NASDAQ:CVAC) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $(0.17) by 929.41 percent. This is a 687.5 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $63.295 million which beat the analyst consensus estimate of $14.520 million by 335.92 percent. This is a 249.02 percent increase over sales of $18.135 million the same period last year.